Incyte Corporation
INCY
#946
Rank
$25.970 B
Marketcap
United States
Country
$128.12
Share price
5.82%
Change (1 day)
47.49%
Change (1 year)
Categories
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive…
Key Metrics
Trailing P/E
16.22
Forward P/E
14.33
EPS (TTM)
$7.85
Forward EPS
$8.89
Price / Book
4.03
EV / EBITDA
11.0x
Beta
0.77
Dividend Yield
—
Return on Equity
30.67%
Return on Assets
16.83%
Debt / Equity
0.60
Current Ratio
4.59
Gross Margin
55.66%
Operating Margin
41.90%
Net Profit Margin
27.71%
Free Cash Flow
$1.181B
Charts
Price history and financial performance over time.
Price & Market Cap
Aug 19 – Sep 18
-0.90%
Source: Yahoo Finance daily closes. Market cap uses the closest quarterly shares-outstanding filing for each date.
Revenue & Net Income
Annual · USD
RevenueNet Income
Latest Revenue$5.141B
Latest Net Income$1.287B
Reporting periods4
Source: Yahoo Finance annual income statements. Year is the fiscal-year end. Most recent period may be trailing-twelve-month (TTM) until the next 10-K is filed.
Compare Incyte Corporation with competitors
Side-by-side market cap, revenue, and financial comparison.
Latest News
Latest News
INCY
No recent news available. Set FINNHUB_API_KEY to enable news.
